echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui SHR6390 plans to be included in the breakthrough therapy CDK4/6 inhibitor melee is about to start

    Hengrui SHR6390 plans to be included in the breakthrough therapy CDK4/6 inhibitor melee is about to start

    • Last Update: 2021-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Hengrui Pharmaceuticals innovative drug SHR6390 tablets were included in the list of proposed breakthrough treatments by the Drug Evaluation Center of the National Medical Products Administration.


    Source: CDE

    SHR6390 is an oral, high-efficiency and selective small molecule CDK4/6 inhibitor developed by Jiangsu Hengrui, which belongs to the first class of chemical drugs.


    Introduction to CDK4/6 Inhibitors

    Introduction to CDK4/6 Inhibitors

    Cyclin Dependent Kinase (CDK) is a key kinase involved in cell cycle regulation.


    CDK4/6 inhibitor approval status

    CDK4/6 inhibitor approval status

    In recent years, CDK4/6 inhibitors are rapidly changing the treatment pattern of HR+ and HER2- advanced breast cancer.


    Pfizer’s piperacillil no longer leads the way, CDK4/6 inhibitor melee is about to start

    Pfizer’s piperacillil no longer leads the way, CDK4/6 inhibitor melee is about to start

    As the first CDK4/6 inhibitor drug to be marketed, Pfizer's piperacillil has an obvious first-mover advantage.


    It can be said that piperacillil dominates the CDK4/6 inhibitor market, and even if reboxilil and abecilil are listed afterwards, they have not been able to shake its market position.


    In fact, on December 18, 2020, Qilu Pharmaceutical's 4 generic drugs, piperacillil capsules, have been approved for marketing by NMPA, which is the first imitation of this variety, and its indication is the first-line combination of aromatase inhibitors for the treatment of postmenopausal patients.


    (Source: CDE)

    In short, CDK 4/6 is a star target, and many companies are developing innovative drugs in the country.


    Reference source:

    1.


    3.


    4.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.